Literature DB >> 16309879

Organotypic human vaginal-ectocervical tissue model for irritation studies of spermicides, microbicides, and feminine-care products.

Seyoum Ayehunie1, Chris Cannon, Sarah Lamore, Joseph Kubilus, Deborah J Anderson, Jeffrey Pudney, Mitchell Klausner.   

Abstract

A three-dimensional organotypic vaginal-ectocervical (VEC) tissue model has been developed to test the irritation of topically applied spermicides, microbicides, and vaginal-care products. The in vitro tissue model was reconstructed using normal VEC epithelial cells and is well stratified, containing differentiated basal, suprabasal, intermediate, and superficial cell layers similar to in vivo tissue. The intermediate and superficial cell layers contain glycogen, and the expression of cytokeratins 13 and 14 in the tissue also parallels that of native tissue. The MTT viability assay and histological assessment were used to test inter-lot and intra-lot reproducibility. The MTT average intra-lot coefficient of variation (CV) was less than 10% and the time required to reduce tissue viability by 50% (ET-50) following application of 1% Triton X-100 averaged 1.25+/-0.24h (n=23) upon completion of the 11-day culture period and 1.30 h+/- 0.19 for the same tissues stored overnight at 4 degrees C on agarose gels. The utility of the VEC model for irritation studies was examined by testing commercially available products using the MTT assay and histological assessment. The average ET-50 values ranged between 1.8 and 2.7h for feminine washes, 3.9-6.7 h for spermicides, 6.8-18 h for anti-itch creams, and >18 h for douches, lubricants, and anti-fungal creams. Studies of cytokines released from VEC cultures following product application showed that elevated concentrations of IL-1alpha and IL-1beta were associated with toxicity of test materials. In conclusion, the VEC tissue model is a highly reproducible, non-animal means to assess the irritation of contraceptives, microbicides, and vaginal-care products.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16309879     DOI: 10.1016/j.tiv.2005.10.002

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  36 in total

1.  Mode of action and safety of lactosporin, a novel antimicrobial protein produced by Bacillus coagulans ATCC 7050.

Authors:  S Riazi; S E Dover; M L Chikindas
Journal:  J Appl Microbiol       Date:  2012-07-24       Impact factor: 3.772

2.  Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition.

Authors:  A C Hearps; D Tyssen; D Srbinovski; L Bayigga; D J D Diaz; M Aldunate; R A Cone; R Gugasyan; D J Anderson; G Tachedjian
Journal:  Mucosal Immunol       Date:  2017-04-12       Impact factor: 7.313

Review 3.  On the genealogy of tissue engineering and regenerative medicine.

Authors:  Himanshu Kaul; Yiannis Ventikos
Journal:  Tissue Eng Part B Rev       Date:  2014-12-23       Impact factor: 6.389

4.  Preclinical evaluation of UC781 microbicide vaginal drug delivery.

Authors:  Meredith R Clark; Timothy J McCormick; Gustavo F Doncel; David R Friend
Journal:  Drug Deliv Transl Res       Date:  2011-04       Impact factor: 4.617

5.  Activity and safety of synthetic lectins based on benzoboroxole-functionalized polymers for inhibition of HIV entry.

Authors:  Alamelu Mahalingam; Anthony R Geonnotti; Jan Balzarini; Patrick F Kiser
Journal:  Mol Pharm       Date:  2011-09-26       Impact factor: 4.939

6.  Engineering a degradable polyurethane intravaginal ring for sustained delivery of dapivirine.

Authors:  Manpreet Kaur; Kavita M Gupta; Azadeh E Poursaid; Prasoona Karra; Alamelu Mahalingam; Hyder A Aliyar; Patrick F Kiser
Journal:  Drug Deliv Transl Res       Date:  2011-06       Impact factor: 4.617

7.  An Intravaginal Ring for the Simultaneous Delivery of an HIV-1 Maturation Inhibitor and Reverse-Transcriptase Inhibitor for Prophylaxis of HIV Transmission.

Authors:  Shweta R Ugaonkar; Justin T Clark; Lexie B English; Todd J Johnson; Karen W Buckheit; Robert J Bahde; Daniel H Appella; Robert W Buckheit; Patrick F Kiser
Journal:  J Pharm Sci       Date:  2015-07-06       Impact factor: 3.534

8.  Trichomonas vaginalis lipophosphoglycan triggers a selective upregulation of cytokines by human female reproductive tract epithelial cells.

Authors:  Raina N Fichorova; Radiana T Trifonova; Robert O Gilbert; Catherine E Costello; Gary R Hayes; John J Lucas; Bibhuti N Singh
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

Review 9.  New Systems for Studying Intercellular Interactions in Bacterial Vaginosis.

Authors:  Melissa M Herbst-Kralovetz; Richard B Pyles; Adam J Ratner; Laura K Sycuro; Caroline Mitchell
Journal:  J Infect Dis       Date:  2016-08-15       Impact factor: 5.226

10.  Caveats associated with the use of human cervical tissue for HIV and microbicide research.

Authors:  Deborah J Anderson; Jeffrey Pudney; Danny J Schust
Journal:  AIDS       Date:  2010-01-02       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.